Reported Tuberculosis in the United States, 2016
This report presents summary data for U.S. TB cases reported to the Division of TB Elimination, CDC, during 2016.
Surveillance
Back to Results
Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to support applications for epidemiological and observational research projects on the long-term cardiopulmonary sequelae following treatment for tuberculosis (TB). Investigators should propose additional testing and data collection in existing cohorts of adult and/or pediatric TB participants to better characterize and understand adverse outcomes and morbidity associated with TB disease post treatment in individuals with and without HIV infection.
HIV Data Protection Landscape For EHE Jurisdictions
The map summarizes state laws and regulations that addresses authorities and protections related to the health departments HIV surveillance data release, which is in response to data requests from courts, prosecutors, and law enforcement agencies. It also reflects laws in Priority Jurisdictions included in Phase I of the federal “Ending the HIV Epidemic: Plan for America” (EHE) initiative, which aims to end the HIV epidemic in the United States by 2030.
Youth Risk Behavior Survey Data Summary & Trends Report: 2011–2021
This report provides the most recent surveillance data, as well as 10-year trends, on health behaviors and experiences among high school students in the United States (U.S.) relating to adolescent health and well-being.
HIV Criminalization Legal and Policy Assessment Tool
This assessment tool is designed to help individuals and organizations, including state and local health departments determine the extent to which jurisdiction laws and regulations can impede HIV surveillance, facilitating privacy breaches and criminalizing HIV infections as well as related risk behaviors.
Innovation Health Practices
The United States Agency for International Development (USAID) is issuing this Broad Agency Announcement (BAA) to seek participants to co-create, co-design, co-invest, and collaborate on creating, piloting, and scaling innovative research and development interventions utilizing innovative health practices to help reduce disease and mortality rates worldwide.
Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization.
Co-infection and Cancer (R01 Clinical Trial Not Allowed)
This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be given to co-infections (excluding co-infection with human immunodeficiency virus [HIV]) that engendered novel opportunities for prevention and treatment and focus on understudied populations.
Reported Tuberculosis in the United States, 2021
This 2021 edition of Reported Tuberculosis in the United States reflects ongoing challenges facing the public health and tuberculosis (TB) communities. The report describes information on cases of TB disease reported to CDC since 1993. This year’s report emphasizes cases counted by the reporting areas in 2021 and the ongoing effects of the COVID-19 pandemic on TB surveillance.
Global tuberculosis report 2022
WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This report is updated annually.